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Abstract: Carnitine is an essential molecule
for the transfer of long chain fatty acids
through the inner mitochondrial membrane,
for beta-oxidation (1). The long chain fatty
acids provide a large proportion of the
energy requirement of the myocardium.
Thus, adequate amounts of tissue carnitine
are required to maintain the normal function
of the myocardium (2). Experimental studies
on acute myocardial ischemia and clinical
investigations of patients with congestive
cardiac failure have indicated that the
myocardial carnitine content was significantly
lowered in both conditions, in contrast to
raised or normal blood carnitine (3-5).
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In the present study, alterations in serum
carnitine levels were assessed in patients with
atherosclerotic coronary artery disease (CAD)
who did not exhibit any signs of cardiac
failure. The possibility of a correlation
between serum carnitine levels and the

Introduction
Prior to β-oxidation, long chain fatty acids form CoA
esters in the outer mitochondrial membrane. However,
the mitochondrial membrane is not permeable to these
esters or free CoA. These substances are transported to
the matrix, following their binding to carnitine (6, 7).
Carnitine is widely distributed in mammalian tissues,
principally in the cardiac and skeletal muscle (1). Since the
muscle tissue comprises a large proportion of the body
mass, it is a major site of fatty acid oxidation. This
process is extremely important in the cardiac tissue,
which supplies approximately 60% of its energy
requirement from the oxidation of fatty acids (2).
Experimental studies revealed that one third of the
myocardial carnitine content was lost within the first 10
minutes of acute myocardial ischemia, and half the
amount in 30 minutes. An elevation in the levels of acetyl
and long chain acylcarnitine esters was also detected

severity of the disease was also investigated
in these patients. The subjects were assessed
angiographically, and grouped according to
the severity of the coronary artery disease
(CAD) as control (n=15) and patients having
mild (n=15), moderate (n=15), and severe
(n=20) CAD. Serum free L-carnitine levels
were measured in all of these groups by an
enzymatic spectrophotometric method.
There were no significant differences
between the serum carnitine levels of the
controls and mild and moderate CAD
patients. On the other hand, a marked
difference was observed between controls
and the severe CAD patients (P< O.O1).These
results imply that serum carnitine
measurements cannot be used to define the
presence of CAD, but they can be markers of
advanced atherosclerotic lesions.
Key Words: Carnitine, Coronary artery
Disease (CAD).

during this period (3). In addition, postmortem
examination of tissues with myocardial infarction
disclosed a depression in the myocardial carnitine content
(8). In a study in which carnitine levels in serum and
endomyocardial biopsy tissues in patients with congestive
cardiac failure due to various causes were measured,
Regitz et al. noticed decreased tissue carnitine and
increased serum carnitine (4). Another study, conducted
by Pierpont et al. on patients with congestive cardiac
failure, revealed diverse results in myocardial tissue
carnitine levels, and a significant rise in plasma carnitine
concentrations (5). Matsui et al. showed that acylcarnitine
release was high in patients with more severe cardiac
failure and concluded that there was a possible carnitine
deficiency in these patients (9).
Carnitine loss from the myocardium as a result of any
of the causal conditions, causes some metabolic
alterations. In particular, the inhibition of adenine
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nucleotide translocase in the mitochondrial membrane
due to the accumulation of acyl-CoA in the sarcoplasma
has a negative effect on the contraction of the
myocardium (3, 8). To our knowledge, carnitine levels in
coronary heart disease patients without cardiac failure
had not been assessed previously. Hence, demonstration
of changes in serum carnitine concentrations and
investigation of the existence of a correlation between
serum carnitine and the severity of coronary heart disease
were the aims of the present study.
Materials and Methods
The study group comprised 65 subjects who attended
and were diagnosed in the Department of Cardiology in
Ege University, Faculty of Medicine. Serum samples were
obtained from the patients before angiography. Following
angiography, the subjects were grouped as control
(n=15), and mild (n=15), moderate (n=15), and severe
(n=20) CAD patients according to the severity of their
disease. The control group consisted of fifteen patients (5
women, 10 men) who attended the Cardiology
Outpatient Clinic of the same hospital due to various types
of heart disease, and who had had an angiographic
assessment. According to the angiographical examination
results, the coronary arteries of all these patients were
normal.
The Gensini scoring system was used to establish the
grouping of the subjects (10). According to this system,
the patient groups were determined to be mild CAD
(n=15, 5 women, 10 men, Gensini score: 1-10),
Table 1.

Results
Subject data and cardiac hemodynamic parameters
are shown in Table 1. Serum urea, creatinine and free L-

Subject data and cardiac hemodynamic parameter values of controls and patients (mean ± SD).

Subject groups

n
Sex : Male
Female
Age (years)
EF (%)
LVEDP
(mm Hg)
RVEDP
(mm Hg)
LVESP
(mm Hg)
RVESP
(mm Hg)
NS: not significant.
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moderate CAD (n=15, 4 women, 11 men, Gensini score:
10-50) and severe CAD (n=20, 6 women, 14 men,
Gensini score: > 50) patients. Cardiac and renal failure
has been reported to have effects on the serum carnitine
levels in various studies. Thus, the patients in the present
study were selected from subjects without cardiac and
renal failure. Subjects with a serum urea of less than 8.33
mmol/L and serum creatinine less than 88.4 mmol/L were
included in the study. To exclude cardiac failure, patients
were selected with regard to the following parameters:
ejection fraction >55%, right ventricular end-diastolic
pressure (RVEDP) 3-7 mm Hg, left ventricular enddiastolic pressure (LVEDP) 7-12 mm Hg, right ventricular
end-systolic pressure (RVESP) 15-30 mm Hg, left
ventricular end-systolic pressure (LVESP) 100-140 mm
Hg. Serum samples obtained from the patients were
centrifuged at 3000g for 15 minutes, transferred to
plastic basins and kept at -20°C until analysis. Samples
were conserved for a maximum period of four months
before analysis. Serum free L-carnitine levels were
measured by an enzymatic UV kit (Boehringer Mannheim
GMBH, Mannheim, Germany) in which the amount of Lcarnitine was quantitated by the amount of NADH
consumed. Results are expressed as mean ± SD and
statistical analyses were performed by Student’s t-test. A
p value of < 0.05 was considered significant.

Control

Mild CAD

Moderate CAD

Severe CAD

P

15
10
5
54.13±11.26
64.67±6.11

15
10
5
53.47±10.02
66.33±6.93

15
11
4
60.27±9.74
65.00±7.32

20
14
6
57.30±10.85
63.25±5.68

NS
NS

10.14±1.35

9.53±1.68

8.2±1.97

9.7±1.56

NS

5.53±1.12

5.33±1.23

5.33±1.17

5.15±1.18

NS

126.27±9.85

127.33±9.42

128.67±8.96

124.75±11.29

NS

23.73±4.78

22.33±4.57

24.00±5.07

23.25±4.67

NS
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carnitine levels are presented in Table 2. Figure 1
represents the graphical evaluation of the free L-carnitine
levels of the study groups. Serum free L-carnitine levels
were found to be 40.32 ±8.9, 38.95 ± 10.6, 45.90 ±
9.4 and 63.15 ± 12.4 µmol/L in the control, mild,
moderate, and severe CAD patient groups, respectively.
No statistical significance could be detected between
serum carnitine levels of the control group and the mild
CAD patient group (p > 0.5). Similarly, although the
serum carnitine concentrations were slightly higher in the
moderate CAD patient group than in the control group,
this difference was not statistically significant (p > 0.5).
However, serum carnitine levels of the severe CAD
patients were significantly higher than those of the
control group (p < 0.01).
Discussion
In studies on carnitine levels in various pathologic
conditions, severe cardiac and renal failure are considered
among the major factors that contribute to the elevation
of blood carnitine levels (11). Therefore, these pathologic
conditions were excluded in the present study by
evaluating the patients with regard to urea and creatinine
concentrations and the hemodynamic criteria of cardiac
failure. High concentrations of serum carnitine in severe
coronary heart disease could be attributed to the loss of
carnitine from the myocardial tissue. The reason for this
loss may be the nonspecific injury of the membrane due
to ischemia. Although carnitine principally functions in the
mitochondria, a great proportion (90%) of this molecule
is in the cytoplasm of the myocardium (4).
In addition to the direct loss of carnitine due to
ischemic membrane injury, the uptake of carnitine by the
myocardium may also be hindered by the disturbance of
the carnitine-deoxycarnitine exchange mechanism in the
membrane (4). Some authors indicate that the clearance
of carnitine released from the ischemic cardiac tissue by

the enhancement of the renal clearence mechanism,
prevents the elevation of plasma carnitine levels (11,
12). The analysis of plasma carnitine levels in various
diseases in these studies demonstrated that the levels
increased only in patients with severe renal failure.
Carnitine is rapidly excreted from the kidneys, that is,
24 hours after the intravenous administration of
carnitine, 83.5% was shown to be excreted in the urine
(8). It is still controversial how a substance excreted so
rapidly can remain elevated in blood. We propose two
possible reasons for this. One reason could be that
carnitine released from the ischemic muscle tissue exceeds
the capacity of renal clearance, or the renal reabsorption
increases secondary to the deficiency in the muscle.
Another reason may be the increase in hepatic and renal
synthesis of carnitine in response to the deficiency in the
muscle (carnitine cannot be synthesized in the muscle),
consequently, this acceleration of the carnitine cycle may
cause an elevation in the plasma concentration. The
relative stability of serum carnitine levels in the mild and
moderate CAD patients may be attributed to the renal
clearance of carnitine possibly released from the
myocardium. In severe disease conditions however,
released carnitine levels might exceed the renal threshold
and plasma levels may rise. Simultaneous analyses of
carnitine in blood and in biopsy specimens from ischemic
myocardium of angiographically staged patients will
certainly serve to enlighten these controversies.
In conclusion, loss of myocardial carnitine may
augment destruction caused by ischemia and contribute
to the development of irreversible cardiac failure. In this
case administration of carnitine along with other treating
agents might be beneficial for the performance of the
myocardium. The high levels of carnitine may be
considered an indication for carnitine therapy.
The statistically insignificant difference in serum
carnitine levels of the mild and moderate CAD cases in

Table 2.
Subject groups

Carnitine
(µmol / L)
Urea)
(mmol / L)
Creatinine
(mmol / L)

Control

Mild CAD

Moderate CAD

Severe CAD

40.32±8.9

38.95±10.06

45.90±9.4

63.15±12.4**

12.87±1.84

14.16±1.92

13.96±2.07

13.94±2.47

70.72±12.37

65.41±14.14

70.72±12.37

71.60±9.72

Serum carnitine, urea and
creatinine values of
patients and controls
(mean ± SD).

** p < 0.01.
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Serum carnitine levels in the four different groups of subjects.

comparison with the controls suggests that serum
carnitine cannot be used as a marker for the presence of
CAD, instead it can only be indicative of advanced
atherosclerotic lesions.
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